Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxytrol Switch For OAB Surfaces Questions On Delayed Diagnoses

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s application to switch the overactive bladder drug Oxytrol for Women must prove to FDA’s OTC advisors that women suffering urinary incontinence due to urinary tract infections, diabetes or other conditions appropriately can discontinue treatment and seek medical attention.

Advertisement

Related Content

Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting
Asthma Treatment OTC Switches Would Face Tough Barriers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel